Abstract
The monoclonal antibody (Mab) 131I-MOv18 was administered to 30 patients with ovarian carcinoma intravenously (n = 20) and intraperitoneally (n = 10). After intraperitoneal administration, higher tumour uptake (mean values 1.3% vs. 0.8%) and a better tumour/background ratio (mean values 2.8 vs. 1.9) than after intravenous injection were obtained. Moreover, after intraperitoneal administration the uptake in non-affected organs, such as liver and spleen, was lower. However, occasionally the favourable results of the intraperitoneal route were cancelled by persistent pelvic non-specific accumulations of 131I-MOv18. The possibility to change the biodistribution pattern in the latter cases with peritoneal washing was evaluated. 3 patients were submitted to this procedure and an improvement in the radiotracer biodistribution was obtained in 1 case. With regard to tumour detection, the average sensitivity (73%) showed a significant difference from the sensitivities for abdominal (61%) and pelvic lesions (90%). No false positive results were noted.
| Original language | English |
|---|---|
| Pages (from-to) | 724-729 |
| Number of pages | 6 |
| Journal | European Journal of Cancer and Clinical Oncology |
| Volume | 27 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - 1991 |
Fingerprint
ASJC Scopus subject areas
- Oncology
- Cancer Research
Cite this
Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody. / Crippa, F.; Buraggi, G. L.; Di Re, E.; Gasparini, M.; Seregni, E.; Canevari, S.; Gadina, M.; Presti, M.; Marini, A.; Seccamani, E.
In: European Journal of Cancer and Clinical Oncology, Vol. 27, No. 6, 1991, p. 724-729.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Radioimmunoscintigraphy of ovarian cancer with the MOv18 monoclonal antibody
AU - Crippa, F.
AU - Buraggi, G. L.
AU - Di Re, E.
AU - Gasparini, M.
AU - Seregni, E.
AU - Canevari, S.
AU - Gadina, M.
AU - Presti, M.
AU - Marini, A.
AU - Seccamani, E.
PY - 1991
Y1 - 1991
N2 - The monoclonal antibody (Mab) 131I-MOv18 was administered to 30 patients with ovarian carcinoma intravenously (n = 20) and intraperitoneally (n = 10). After intraperitoneal administration, higher tumour uptake (mean values 1.3% vs. 0.8%) and a better tumour/background ratio (mean values 2.8 vs. 1.9) than after intravenous injection were obtained. Moreover, after intraperitoneal administration the uptake in non-affected organs, such as liver and spleen, was lower. However, occasionally the favourable results of the intraperitoneal route were cancelled by persistent pelvic non-specific accumulations of 131I-MOv18. The possibility to change the biodistribution pattern in the latter cases with peritoneal washing was evaluated. 3 patients were submitted to this procedure and an improvement in the radiotracer biodistribution was obtained in 1 case. With regard to tumour detection, the average sensitivity (73%) showed a significant difference from the sensitivities for abdominal (61%) and pelvic lesions (90%). No false positive results were noted.
AB - The monoclonal antibody (Mab) 131I-MOv18 was administered to 30 patients with ovarian carcinoma intravenously (n = 20) and intraperitoneally (n = 10). After intraperitoneal administration, higher tumour uptake (mean values 1.3% vs. 0.8%) and a better tumour/background ratio (mean values 2.8 vs. 1.9) than after intravenous injection were obtained. Moreover, after intraperitoneal administration the uptake in non-affected organs, such as liver and spleen, was lower. However, occasionally the favourable results of the intraperitoneal route were cancelled by persistent pelvic non-specific accumulations of 131I-MOv18. The possibility to change the biodistribution pattern in the latter cases with peritoneal washing was evaluated. 3 patients were submitted to this procedure and an improvement in the radiotracer biodistribution was obtained in 1 case. With regard to tumour detection, the average sensitivity (73%) showed a significant difference from the sensitivities for abdominal (61%) and pelvic lesions (90%). No false positive results were noted.
UR - http://www.scopus.com/inward/record.url?scp=0025898716&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0025898716&partnerID=8YFLogxK
U2 - 10.1016/0277-5379(91)90174-C
DO - 10.1016/0277-5379(91)90174-C
M3 - Article
VL - 27
SP - 724
EP - 729
JO - European Journal of Cancer
JF - European Journal of Cancer
SN - 0959-8049
IS - 6
ER -